ANDOVER,
Mass., Oct. 29, 2024 /PRNewswire/ -- TransMedics
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology
company that is transforming organ transplant therapy for patients
with end-stage lung, heart, and liver failure, today announced
that on October 23, 2024, TransMedics
granted non-qualified stock options to purchase an aggregate of
2,969 shares of its common stock and an aggregate of 1,937
restricted stock units to 6 employees, each as a material
inducement for each employee's entry into employment with
TransMedics. The grants were approved by the Compensation Committee
of the TransMedics Board of Directors and were granted in
accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the
TransMedics Group, Inc. Inducement Plan.
TransMedics granted non-qualified stock options to purchase
2,969 shares of TransMedics' common stock and 1,937 restricted
stock units in the aggregate. The stock options were granted with a
per share exercise price of $118.66,
the closing price of the common stock on the Nasdaq Global Market
on October 23, 2024. Twenty-five
percent of the shares subject to each option will vest on the first
yearly anniversary of the date of the employee's start of
employment, with the remainder vesting in equal monthly
installments over the subsequent three year period, subject to the
employee's continued service with the Company through the
applicable vesting date. The options have a 10-year term and are
subject to the terms of the TransMedics Group, Inc. Inducement
Plan. Twenty-five percent of each restricted stock unit award will
vest on the first four anniversaries of the date of the employee's
start of employment, subject to the employee's continued service
with the Company through the applicable vesting date. The
restricted stock units are subject to the terms of the TransMedics
Group, Inc. Inducement Plan.
About TransMedics Group, Inc.
TransMedics is the
world's leader in portable extracorporeal warm perfusion and
assessment of donor organs for transplantation. Headquartered in
Andover, Massachusetts, the
company was founded to address the unmet need for more and better
organs for transplantation and has developed technologies to
preserve organ quality, assess organ viability prior to transplant,
and potentially increase the utilization of donor organs for the
treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian
Johnston
332-895-3222
Investors@transmedics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302290516.html
SOURCE TransMedics Group, Inc.